Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04405401 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Stereotactic Ablative Radiotherapy for Oligo-Progressive Non Small Cell Lung Cancer

Study acronym: SUPPRESS-NSCLC
StatusTerminated
PhasePhase 2
Started2021-01-05
View on ClinicalTrials.gov ↗

Amendment history

2026-09-29
Trial terminated: Poor accrual
Final enrollment: 52 participants (planned 68)
Primary completion confirmed: January 2026 (last estimated December 2026)
2026-07-21
Recruiting→Active, Not Recruiting Study Status, Contacts/Locations v6
Trial statusRecruiting→Active, Not Recruiting
Primary completion date2025-07-01→2026-12-01
Completion date2027-07-01→2028-07-01
Study sitesdetails revised at 1 of 1 site
2023-12-11
Study Status v5
Primary completion date2023-07-01→2025-07-01
Completion date2025-07-01→2027-07-01
2023-04-24
Study Identification, Study Status, Sponsor/Collaborators v4
Re-verified, no change to tracked fields
2022-04-24
Study Identification, Study Status, Sponsor/Collaborators v3
Collaborators-11 characters
AstraZeneca
Show 2 earlier versions
2021-02-19
Not Yet Recruiting→Recruiting Study Status, Study Design, Contacts/Locations v2
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2020-06-30→confirmed 2021-01-05
Study sitesdetails revised at 1 of 1 site
2020-05-31
Study Status, Sponsor/Collaborators, Contacts/Locations v1
Collaborators+11 characters
AstraZeneca
2020-05-27
Original filing
A registry-based randomized screening phase II trial. A total of 68 patients with metastatic non small cell lung cancer on systemic therapy with oligoprogression to 1-5 extracranial lesions will be randomized using a 1:1 ratio to standard of care (begin next-line systemic therapy, best supportive care, continue current systemic line, based on treating physician decision) vs. receive stereotactic ablative radiotherapy to all oligoprogressive lesions while continuing their current systemic therapy.
Trial Details
NCT Number NCT04405401
Lead Sponsor Centre hospitalier de l'Université de Montréal (CHUM)
Conditions Lung Cancer Metastatic
Enrollment 52 participants
Start Date 2021-01-05
Primary Completion 2026-01-06 (estimated)
Study Completion 2026-09-24 (estimated)
Updated on ClinicalTrials.gov 2026-09-28